Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight-based versus fixed-dose normal human immunoglobulin for hepatitis A post-exposure prophylaxis
ACTRN12617001567314Phase 4Terminated
- Sponsor
- Griffith University
- Start
- May 2018
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of NPB-01-ME in hepatitis A (HAV) (2 arms), sponsored by Griffith University. Primary endpoint: Quantitative hepatitis A antibody concentration in serum at day 50. Started May 2018; status: terminated.
02
Drugs
NPB-01-ME
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on ACTRN12617001567314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001567314.